D
Dana Patsch
Researcher at University of Pennsylvania
Publications - 7
Citations - 1987
Dana Patsch is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Antigen & CD8. The author has an hindex of 3, co-authored 7 publications receiving 1598 citations.
Papers
More filters
Journal ArticleDOI
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Christina Twyman-Saint Victor,Andrew J. Rech,Amit Maity,Ramesh Rengan,Ramesh Rengan,Kristen E. Pauken,Erietta Stelekati,Joseph L. Benci,Bihui Xu,Hannah Dada,Pamela M. Odorizzi,Ramin S. Herati,Kathleen D. Mansfield,Dana Patsch,Ravi K. Amaravadi,Lynn M. Schuchter,Hemant Ishwaran,Rosemarie Mick,Daniel A. Pryma,Xiaowei Xu,Michael Feldman,Tara C. Gangadhar,Stephen M. Hahn,E. John Wherry,Robert H. Vonderheide,Andy J. Minn +25 more
TL;DR: Major tumour regressions are reported in a subset of patients with metastatic melanoma treated with an anti-CTLA4 antibody and radiation and reproduced this effect in mouse models, showing that PD-L1 on melanoma cells allows tumours to escape anti- NCTLA4-based therapy, and the combination of radiation, anti- CTLA4 and anti-PD-L 1 promotes response and immunity through distinct mechanisms.
Journal ArticleDOI
A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours.
Amit Maity,Rosemarie Mick,Alexander C. Huang,Sangeeth M. George,Michael D. Farwell,John N. Lukens,Abigail T. Berman,Tara C. Mitchell,Josh Bauml,Lynn M. Schuchter,Mark H. O'Hara,Lilie L. Lin,Angela DeMichele,John P. Christodouleas,Naomi B. Haas,Dana Patsch,Stephen M. Hahn,Andy J. Minn,E. John Wherry,Robert H. Vonderheide +19 more
TL;DR: HFRT was well tolerated with pembrolizumab, and in some patients with metastatic NSCLC or melanoma, it reinvigorated a systemic response despite previous progression on anti-PD-1 therapy.
Journal ArticleDOI
Clinical Outcomes of the HIV Protease Inhibitor Nelfinavir With Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non–Small Cell Lung Cancer: A Phase 1/2 Trial
Ramesh Rengan,Ramesh Rengan,Rosemarie Mick,Daniel A. Pryma,Lilie Leming Lin,John P. Christodouleas,John P. Plastaras,Charles B. Simone,Anjali K. Gupta,Tracey L. Evans,James P. Stevenson,Corey J. Langer,John C. Kucharczuk,Joseph S. Friedberg,Sarah Lam,Dana Patsch,Stephen M. Hahn,Amit Maity +17 more
TL;DR: It is suggested that nelfinavir administered with concurrent CT-RT is associated with acceptable toxic effects and a promising objective response rate, local failure, progression-free survival, and overall survival in unresectable LA-NSCLC.
Journal ArticleDOI
A stratified phase I dose escalation trial of hypofractionated radiotherapy followed by ipilimumab in metastatic melanoma: long-term follow-up and final outcomes
Amit Maity,Rosemarie Mick,Ramesh Rengan,Tara C. Mitchell,Ravi K. Amaravadi,Lynn M. Schuchter,Daniel A. Pryma,Dana Patsch,A. Maity,Andy J. Minn,Robert H. Vonderheide,John N. Lukens +11 more
TL;DR: In this paper, the authors conducted a phase I dose-escalation trial of radiation with ipilimumab in patients with melanoma with ≥ 2 metastatic lesions and reported the final full clinical analysis.
Journal ArticleDOI
Long-term Results of a Phase I/II Trial of Nelfinavir with Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer
Ramesh Rengan,Rosemarie Mick,Daniel A. Pryma,L.L. Lin,John P. Plastaras,Charles B. Simone,Anjali K. Gupta,Tracey L. Evans,James P. Stevenson,Corey J. Langer,John C. Kucharczuk,Joseph S. Friedberg,Sarah Lam,Dana Patsch,Stephen M. Hahn,A. Maity +15 more